Zai Lab Reports Q1 2026 Revenue of $99.6 Million, Net Loss of $51.0 Million

Zai Lab Limited reported its financial results for the first quarter of 2026, revealing a total revenue of $99.6 million, a decrease of 6% from $106.5 million in the same period last year. The decline was primarily driven by a 10% drop in product revenue, which fell to $95.6 million from $105.7 million, largely due to reduced sales of its flagship product ZEJULA and pricing adjustments for VYVGART. Collaboration revenue, however, saw a significant increase, rising to $4.1 million from $0.8 million, attributed to a regional licensing agreement.

The company's net loss for the quarter was $51.0 million, or $0.05 per share, compared to a net loss of $48.4 million, or $0.04 per share, in the prior year. This increase in loss was influenced by higher research and development expenses, which rose by 8% to $65.6 million, reflecting ongoing investments in clinical trials and product development. Selling, general, and administrative expenses also increased slightly by 3% to $65.1 million, indicating continued operational costs associated with its commercial activities.

In terms of operational developments, Zai Lab has made strides in its clinical pipeline, particularly in oncology. The company presented promising data for its DLL3-targeting ADC, Zocilurtatug Pelitecan, at the AACR Annual Meeting, demonstrating significant intracranial response rates in patients with small cell lung cancer. Additionally, Zai Lab announced a global clinical trial collaboration with Amgen to evaluate Zoci in combination with Amgen’s bispecific T-cell engager, further expanding its research initiatives.

Geographically, Zai Lab continues to focus on its core markets in Greater China and the United States, with plans to enhance its product offerings and market penetration. The company reported a cash position of $752.4 million as of March 31, 2026, which it expects will support its operational needs for at least the next 12 months. Looking ahead, Zai Lab anticipates continued fluctuations in financial performance as it balances the commercialization of its products with substantial ongoing investments in research and development. The company remains committed to advancing its pipeline and expanding its market presence, despite the challenges posed by competitive pressures and regulatory environments.